Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Sun Pharma Lands 483 As GMP Deficiencies Continue to Plague Facility

  • Post author:Sam
  • Post published:January 17, 2017
  • Post category:Drug GMP Report

Nearly a year after Sun Pharma began implementing a remediation plan to resolve GMP deficiencies at its Halol, India facility, the FDA continues to fault the company for failing to…

Continue ReadingSun Pharma Lands 483 As GMP Deficiencies Continue to Plague Facility

Spanish Drugmaker Sued for Off-Label Promotion of Thrombate III

  • Post author:Sam
  • Post published:January 17, 2017
  • Post category:Drug GMP Report

Spanish drugmaker Grifols is accused of defrauding the government of millions of dollars for promoting the use of its antithrombin drug, Thrombate III, in unapproved indications. Source: Drug GMP Report

Continue ReadingSpanish Drugmaker Sued for Off-Label Promotion of Thrombate III

Two International Drug Manufacturers Earn Warning Letters

  • Post author:Sam
  • Post published:January 17, 2017
  • Post category:Drug GMP Report

The FDA issued warning letters to two international drug manufacturers for breaching GMP standards by failing to develop procedures to maintain the appropriate quality controls. Source: Drug GMP Report

Continue ReadingTwo International Drug Manufacturers Earn Warning Letters

Polydrug Lands FDA Warning Letter on Post-ban Data Integrity Claims

  • Post author:Sam
  • Post published:June 13, 2016
  • Post category:Drug GMP Report

The FDA has slapped Polydrug Laboratories’ Mumbai facility with a warning letter for alleged GMP deviations seven months after it received a ban on U.S. imports. Source: Drug GMP Report

Continue ReadingPolydrug Lands FDA Warning Letter on Post-ban Data Integrity Claims

FDA Letter Blasts Infusion Options Over Sterility Concerns at Facility

  • Post author:Sam
  • Post published:June 13, 2016
  • Post category:Drug GMP Report

The FDA has handed Infusion Options a warning letter for a slew of GMP deficiencies in compounding sterile products and failing to meet 503B conditions for outsourced compounding operations. Source:…

Continue ReadingFDA Letter Blasts Infusion Options Over Sterility Concerns at Facility

FDA Serves Four Drugmakers With Form 483s on GMP Concerns

  • Post author:Sam
  • Post published:June 13, 2016
  • Post category:Drug GMP Report

The FDA has issued Form 483s to four drugmakers in the past month over a variety of GMP lapses at their facilities. Source: Drug GMP Report

Continue ReadingFDA Serves Four Drugmakers With Form 483s on GMP Concerns

FDA Letters Slam Four Compounders Over Sterility, Prescription Issues

  • Post author:Sam
  • Post published:June 13, 2016
  • Post category:Drug GMP Report

Four compounders recently received FDA warning letters that faulted them over sterility concerns and other issues. Source: Drug GMP Report

Continue ReadingFDA Letters Slam Four Compounders Over Sterility, Prescription Issues

Xellia, FDA Modify Consent Decree; Site Can Resume Production by 2017

  • Post author:Sam
  • Post published:June 13, 2016
  • Post category:Drug GMP Report

Xellia Pharmaceuticals and the FDA have agreed on a modified consent decree so Xellia can resume manufacturing at the Bedford, Ohio, site it purchased from Ben Venue Laboratories. Source: Drug…

Continue ReadingXellia, FDA Modify Consent Decree; Site Can Resume Production by 2017

FDA Targets Five Supplement Makers on Claims, Batch Production Records

  • Post author:Sam
  • Post published:June 13, 2016
  • Post category:Drug GMP Report

The FDA has zeroed in on five dietary supplement makers in recent weeks, complaining of a laundry list of issues that range from promotional claims to GMP problems. Source: Drug…

Continue ReadingFDA Targets Five Supplement Makers on Claims, Batch Production Records

EU Looks to Harmonize U.S. and EU Rules Covering Approval, Guidelines and GMP

  • Post author:Sam
  • Post published:June 13, 2016
  • Post category:Drug GMP Report

The European Union wants to expand ongoing trade talks between the U.S. and EU to address regulatory harmonization on drug approval requirements, guidelines and GMP compliance. Source: Drug GMP Report

Continue ReadingEU Looks to Harmonize U.S. and EU Rules Covering Approval, Guidelines and GMP
  • Go to the previous page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.